(VIANEWS) – Shares of PHOTOCURE (Oslo Børs All-share Index_GI: PHO.OL) fell by a staggering 13.13% to kr94.95 at 10:41 EST on Thursday, following the last session’s upward trend. Oslo Børs All-share Index_GI is jumping 0.7% to kr1,397.96, after five successive sessions in a row of losses. This seems, up to now, a somewhat positive trend exchanging session today.
PHOTOCURE’s last close was kr110.50, 9.94% below its 52-week high of kr122.70.
About PHOTOCURE
Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, Italy, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, PHOTOCURE has a trailing twelve months EPS of kr-0.84.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -15.67%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 120% and positive 75.6% for the next.
Volatility
PHOTOCURE’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.46%, a negative 0.05%, and a positive 1.11%.
PHOTOCURE’s highest amplitude of average volatility was 0.76% (last week), 0.92% (last month), and 1.11% (last quarter).
Earnings Before Interest, Taxes, Depreciation, and Amortization
PHOTOCURE’s EBITDA is 286.63.
Revenue Growth
Year-on-year quarterly revenue growth grew by 22.2%, now sitting on 383.47M for the twelve trailing months.
More news about PHOTOCURE (PHO.OL).
